CYP2C9 and Hypoalbuminemia: Patient-specific factors, such as hepatic perfusion, enzyme activity (e.g., CYP2B6, CYP2C9), genetic polymorphisms, hypoalbuminemia, age-related changes in clearance, reduced hepatic blood flow due to hypotension, or compromised cardiac output, further influence pharmacokinetic and pharmacodynamic performance.